Our Corporate Philosophy is to give first thought to patients and their families, and increase the benefits that health care provides them. Under this philosophy, the Company endeavors to become a human health care (hhc) company. In FY2016, we launched the medium-term business plan "EWAY 2025." Oncology and neurology have been positioned as the two major therapeutic areas of focus under this plan, and we are engaged in the creation of innovative new drugs. As a global pharmaceutical company, our corporate mission to contribute to the well-being of patients extends around the world. We are taking proactive steps for improvement of access to medicines in developing and emerging countries through collaboration with our major stakeholders.
We ask all of our stakeholders for their continued support going forward.
Representative Corporate Officer and CEO